文献速递姑息放疗与转移瘤放疗物理与技术

脊柱转移瘤多分次立体定向体部放疗的局部失败与椎体骨折风险

Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases.
PubMed 文献 · Adv Radiat Oncol · 2018-04-10

该回顾性分析纳入2009至2017年在本机构接受2至5次分次立体定向体部放疗(SBRT)的83例患者共98处脊柱转移病灶,中位随访7.6个月。6个月和1年局部控制率分别为93%和84%,椎体骨折(VBF)发生率为4.2%。多分次SBRT局部控制率高且VBF发生率低,提示较单次SBRT具有更有利的治疗比。

要点

  • 83例患者98处脊柱转移灶接受中位24 Gy/3次的多分次SBRT,中位随访7.6个月。
  • 6个月和1年局部控制率分别为93%和84%,VBF总发生率为4.2%。
  • 仅既存VBF预测SBRT后VBF风险(P < .01),更高处方剂量和生物有效剂量等预测更优局部控制。

核心结论

  • 多分次SBRT治疗脊柱转移瘤局部控制率高且VBF发生率低,提示较单次SBRT具有更有利的治疗比。

研究设计与样本

  • 回顾性分析2009至2017年在本机构接受多分次SBRT的脊柱转移瘤患者,采用Cyberknife系统行2至5次分次照射。
  • 共83例患者98处脊柱病灶,中位随访7.6个月,每3至6个月进行临床和磁共振成像随访。

主要发现

  • 6个月局部控制率为93%,1年局部控制率为84%。
  • VBF在所有病例中发生率为4.2%,在SBRT前未接受手术或椎体成形术的病例中为5.3%。
  • 局部失败组与无失败组的累积剂量分别为23 Gy与26 Gy(P = .02),生物有效剂量分别为39 Gy与46 Gy(P = .01),90%计划靶区最低剂量分别为23 Gy与26 Gy(P = .03)。
  • 仅既存VBF预测SBRT后VBF风险(P < .01)。

关键数值与推荐

  • 更高处方剂量、更高生物有效剂量、更高90%计划靶区最低剂量、肿瘤组织学和更小肿瘤体积预测局部控制改善。
  • 中位SBRT剂量为24 Gy,中位分次数为3次。
  • 21%的病例在SBRT前接受了手术或椎体成形术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Single-fraction radiation surgery for spine metastases is highly effective. However, a high rate (20-39%) of vertebral body fracture (VBF) has been associated with large, single-fraction doses. We report our experience using multifraction stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: All patients who were treated with multifraction SBRT for spine metastases at our institution between 2009 and 2017 were retrospectively analyzed. SBRT was delivered in 2 to 5 fractions using the Cyberknife System (Accuray, Sunnyvale, CA). Patients were followed clinically and with magnetic resonance imaging every 3 to 6 months. Local control, complications (including VBF), and overall survival were evaluated. Patient, disease, and treatment variables were analyzed for a statistical association with outcomes. RESULTS: A total of 83 patients were treated to 98 spine lesions with a median follow-up of 7.6 months. Histologies included non-small cell lung cancer (NSCLC; 24%), renal cell carcinoma (RCC; 18%), and breast cancer (12%). Surgery or vertebroplasty were performed before SBRT in 21% of cases. Patients received a median SBRT dose of 24 Gy in a median of 3 fractions. Local control was 93% at 6 months and 84% at 1 year. Higher prescribed dose, higher biologic effective dose, higher minimum dose to 90% of the planning target volume, tumor histology, and smaller tumor volume predicted improved local control. The cumulative dose was 23 Gy versus 26 Gy for patients with and without failure (P = .02), higher biologic effective dose 39 Gy versus 46 Gy, (P = .01), and higher minimum dose to 90% of the planning target volume 23 Gy versus 26 Gy (P = .03). VBF occurred in 4.2% of all cases and 5.3% of those without surgery or vertebroplasty prior to SBRT. Only preexisting VBF predicted risk of post-SBRT VBF (P < .01). CONCLUSIONS: Multifraction SBRT results in a high local control rate for metastatic spinal disease with a low VBF rate, which suggests a favorable therapeutic ratio compared with single-fraction SBRT.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mehta N, Zavitsanos PJ, Moldovan K, et al. Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases. Adv Radiat Oncol. 2018. PMID: 30202794. doi:10.1016/j.adro.2018.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。